RMDC Co., Ltd. (Shibuya-ku, Tokyo; representative director: Nobuhiro Kawabata), a consolidated subsidiary of PAS Co., Ltd. (Tokyo Stock Exchange Standard Market Code: 3840) engaged in regenerative medicine-related businesses (hereinafter referred to as "the Company"), has entered into a joint research agreement with Kobe Gakuin University (School of Pharmacy; Professor Shoji Fukushima), Be-Ryu Co., Ltd., and Uni-Root Co., Ltd. The four parties will begin joint research titled "Pharmaceutical Research on Cancer Treatment Applications through the Integration of Stem Cells and Their Culture Products with Finely Dispersed Graphene" (hereinafter referred to as "this joint research") starting January 1, 2026 (research period: January 1, 2026 – March 31, 2027). The parties have now mutually agreed to publicly announce this joint research. 1. Background and Objectives of the Joint Research In recent years, significant attention has been focused on the application of exosomes and various bioactive factors contained in "stem cell culture supernatant" for tissue repair in medical and cosmetic fields. In this joint research, RMDC will integrate its expertise in stem cells and culture supernatants with the pharmaceutical knowledge of the university and the cutting-edge nanomaterial dispersion technologies of the participating companies. RMDC will particularly focus on effects on the skin, aiming to scientifically analyze and verify safety upon topical application, impact on drug permeability through the skin (drug skin permeability), and efficacy in tissue healing and cancer lesion recovery processes (wound healing) using animal and cultured skin models. (Objectives of the Research) 1. To evaluate the effects of stem cells or stem cell culture supernatant on the skin using animal models and cultured skin, and to explore applications for drug delivery. 2. To study the application of finely dispersed graphene with improved dispersibility for cancer treatment. 3. To apply graphene